

IN THE DISCLOSURE

At page 1, line 3, before 'Field of Invention' please insert ---

*B1*  
~~This Application is a Continuation-In-Part Application of United States Patent Application Serial Number 07/675,908, filed on July 3, 1991 which application was the application entering the National Phase in the United States from PCT Application Serial Number PCT/CA90/00306 which application claims priority from Canada Patent Application Serial Number 612,307-4 filed September 21, 1989---~~

In this regard Applicants have enclosed revised Declarations, Power of Attorney and Petitions executed by Doctors Rudolf Edgar Falk and Samuel Simon Asculai. Each of the documents specifies that this application is a continuation-in-part application of United States Patent Application Serial No. 07/675,908.

IN THE CLAIMS

Please amend the claims as follows:

*B<sup>2</sup>*  
~~1. (Amended) A [topically applied transdermally penetrating systemic independent acting] pharmaceutical [combination and formulation for the] composition comprising in a pharmaceutically acceptable form, a plurality of effective non-toxic dosage amounts of a composition for topical administration to the site of pathology and/or trauma of skin and/or exposed tissue of a human patient in need of treatment [of suffering from a disease or condition of the skin and exposed tissue [for example,] comprising basal cell carcinoma, the precancerous, often recurrent, actinic keratoses lesions, fungal lesions, "liver" spots and like~~